Comparative Pharmacology
Head-to-head clinical analysis: FEBUXOSTAT versus ULORIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEBUXOSTAT versus ULORIC.
FEBUXOSTAT vs ULORIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
None Documented
None Documented
Clinical Note
moderateFebuxostat + Theophylline
"The serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Aminophylline
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Dyphylline
"The serum concentration of the active metabolites of Dyphylline can be increased when Dyphylline is used in combination with Febuxostat."
Clinical Note
moderateTerminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Azathioprine + Febuxostat
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."